These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36199999)

  • 21. Postoperative vaginal cuff irradiation using high dose rate remote afterloading: a phase II clinical protocol.
    Noyes WR; Bastin K; Edwards SA; Buchler DA; Stitt JA; Thomadsen BR; Fowler JF; Kinsella TJ
    Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1439-43. PubMed ID: 7635785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer.
    Dunn EF; Geye H; Platta CS; Gondi V; Rose S; Bradley KA; Anderson BM
    Gynecol Oncol; 2014 Jun; 133(3):494-8. PubMed ID: 24657301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple-tandem high-dose-rate brachytherapy for early-stage medically inoperable endometrial cancer: Initial report on acute toxicity and dosimetric comparison to stereotactic body radiation therapy.
    Kauffmann G; Wu T; Al-Hallaq H; Hasan Y
    Brachytherapy; 2017; 16(1):141-146. PubMed ID: 27866953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaginal-cuff control and toxicity results of a daily HDR brachytherapy schedule in endometrial cancer patients.
    Ríos I; Rovirosa A; Ascaso C; Valduvieco I; Herreros A; Castilla L; Sabater S; Holub K; Pahisa J; Biete A; Arenas M
    Clin Transl Oncol; 2016 Sep; 18(9):925-30. PubMed ID: 26661111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A single-institution review of image-guided brachytherapy for vaginal malignancies using customized molded applicators and interstitial needles.
    Flower E; Zanjani S; Busuttil G; Sullivan E; Smith W; Tran K; Thwaites D; Chard J; Do V
    J Contemp Brachytherapy; 2021 Dec; 13(6):663-669. PubMed ID: 35079253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
    Alektiar KM; Venkatraman E; Chi DS; Barakat RR
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of vaginal cuff brachytherapy followed by dose-dense chemotherapy in early stage endometrial cancer patients with enriched, high-intermediate risk factors for recurrence.
    Castellano T; John Maxwell IV; Adam Walter J; Thompson S; McMeekin DS; Landrum LM
    Gynecol Oncol; 2021 Mar; 160(3):669-673. PubMed ID: 33358492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage high-dose-rate brachytherapy and external beam radiotherapy for isolated vaginal recurrences of endometrial cancer with no prior adjuvant therapy.
    Chapman CH; Maghsoudi K; Littell RD; Chen LM; Hsu IC
    Brachytherapy; 2017; 16(6):1152-1158. PubMed ID: 28802913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamics of High Risk Clinical Target Volume reduction during Brachytherapy and impact on its coverage in patients with inoperable cervical cancer.
    Pobijakova M; Scepanovic D; Paluga M; Fekete M; Mardiak J
    Neoplasma; 2018 Mar; 65(3):425-430. PubMed ID: 29788726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dosimetric impact of bladder filling on organs at risk with barium contrast in the small bowel for adjuvant vaginal cuff brachytherapy.
    Buzón MDCS; Bayard LG; Sanchez RR; Rodríguez LÁQ; Gil SS; Higueras CM
    J Contemp Brachytherapy; 2021 Dec; 13(6):655-662. PubMed ID: 35079252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outpatient vaginal cuff brachytherapy for endometrial cancer.
    Petereit DG; Tannehill SP; Grosen EA; Hartenbach EM; Schink JC
    Int J Gynecol Cancer; 1999 Nov; 9(6):456-462. PubMed ID: 11240811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Body Mass Index and Doses at Organs at Risk in a Mediterranean Population Treated with Postoperative Vaginal Cuff Brachytherapy.
    Sabater S; Arenas M; Berenguer R; Andres I; Jimenez-Jimenez E; Martos A; Fernandez-Lopez J; Sevillano M; Rovirosa A
    Cancer Res Treat; 2015 Jul; 47(3):473-9. PubMed ID: 25672575
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bladder distension improves the dosimetry of organs at risk during intracavitary cervical high-dose-rate brachytherapy.
    Harmon G; Chinsky B; Surucu M; Harkenrider M; Small W
    Brachytherapy; 2016; 15(1):30-4. PubMed ID: 26521661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EROS 2.0 study: evaluation of two interventional radiotherapy (brachytherapy) schedules for endometrial cancer: a comparison of late vaginal toxicity rates.
    Lancellotta V; Macchia G; Dinapoli N; Autorino R; Campitelli M; Nardangeli A; Salvati A; Fionda B; Casà C; Cornacchione P; Rovirosa A; Kovács G; Morganti AG; Ferrandina MG; Gambacorta MA; Tagliaferri L
    Radiol Med; 2022 Mar; 127(3):341-348. PubMed ID: 35092552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant Pelvic Radiation Therapy±Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid Carcinoma.
    Nagar H; Yan W; Parashar B; Nori D; Chao KS; Christos P; Gupta D; Holcomb K; Caputo T; Wernicke AG
    Am J Clin Oncol; 2016 Aug; 39(4):335-9. PubMed ID: 27028349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overview of adjuvant radiotherapy on survival, failure pattern and toxicity in stage I to II endometrial carcinoma: a long-term multi-institutional analysis in China.
    Wang W; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Hu K; Zhang F; Hou X; Wei L; Zou L
    BMC Cancer; 2022 Mar; 22(1):266. PubMed ID: 35287626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
    Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S
    Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of age on long-term outcome in patients with endometrial cancer treated with postoperative radiation.
    Jolly S; Vargas CE; Kumar T; Weiner SA; Brabbins DS; Chen PY; Floyd W; Martinez AA
    Gynecol Oncol; 2006 Oct; 103(1):87-93. PubMed ID: 16545441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inter-application displacement of brachytherapy dose received by the bladder and rectum of the patients with inoperable cervical cancer.
    Marosevic G; Ljuca D; Osmic H; Fazlic S; Arsovski O; Mileusnic D
    Radiol Oncol; 2014 Jun; 48(2):203-9. PubMed ID: 24991211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dosimetric comparison of brachytherapy sources for high-dose-rate treatment of endometrial cancer: (192)Ir, (60)Co and an electronic brachytherapy source.
    Mobit PN; Nguyen A; Packianathan S; He R; Yang CC
    Br J Radiol; 2016; 89(1059):20150449. PubMed ID: 26743941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.